Study Title: An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)
This trial is closed to accrual. For general questions, please contact the Clinical Trials Office.